EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation

Rohtesh S Mehta iD, Hannah Choe, Jennifer Saultz iD, Zimu Gong, Prashant Sharma, Taha Al-Juhaishi iD, Gabriela S Petitto, Aleksandr Lazaryan, Anurag Singh, Elisabetta Xue iD, Dimana Dimitrova, Mustafa Hyder und 7 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Rohtesh S Mehta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Tissue Donors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection post‐hematopoietic cell transplantation (HCT) remains a significant cause of morbidity and mortality. While letermovir prophylaxis is available for CMV‐seropositive recipients, optimal donor selection for CMV‐seronegative recipients remains unclear, with donor age often prioritized over CMV serostatus. We investigated the relative impact of donor age and CMV serostatus in CMV‐seronegative recipients ( n = 1013) with either CMV‐seropositive ( n = 318) or CMV‐seronegative donors ( n = 695), who underwent HCT with HLA‐matched sibling donors with calcineurin inhibitor‐based or post‐transplant cyclophosphamide (PTCy)‐based graft‐versus‐host disease prophylaxis, or haploidentical donors with PTCy. Multiple conventional and machine‐learning approaches were employed to account for confounding factors. Across all analyses, CMV‐seropositive donor status was consistently associated with significantly inferior overall survival (OS) and disease‐free survival, primarily driven by increased non‐relapse mortality (NRM). Older donor age showed a statistically significant association with OS and DFS in some but not all models, and its effect size was small (about 1% increased hazard per year in Cox proportional hazard model) compared to the substantial impact of CMV‐seropositive donors (about 27%–33% increased hazards for worse OS, approximately 50%–60% higher NRM in Cox proportional hazard model). However, our machine learning model revealed a more nuanced and complex non‐linear effect of donor age, further demonstrating the adverse impact of donor CMV serostatus. Our findings suggest that prioritizing a CMV‐seronegative donor may be associated with improved outcomes in CMV‐seronegative recipients. Further research is needed to validate these findings and explore underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsCytomegalovirusTissue DonorsDonor SelectionHumansMaleFemaleMiddle AgedAdultAge FactorsAdolescentGraft vs Host DiseaseTransplantation, HomologousAgedCyclophosphamideYoung Adult

Stichwörter der Autor:innen

CMVCNIHLA matched sibling donorHaploidenticalPTCycalcineurin inhibitorcytomegalovirusdonor agepost‐transplantation cyclophosphamide

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Division of Hematology/Oncology, Oregon Health and Science University, Portland, Oregon, USA.
  • OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
  • Blood and Marrow Transplant/Acute Leukemia Program, Intermountain Medical Group, Salt Lake City, Utah, USA.
  • Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA.

ORCID-Profile: Rohtesh S Mehta, Jennifer Saultz, Taha Al-Juhaishi, Elisabetta Xue, Shannon McCurdy, Annie Im, Filippo Milano

Förderung

  • NCI NIH HHS

Zitieren

APA

Mehta, R. S., Choe, H., Saultz, J., Gong, Z., Sharma, P., Al-Juhaishi, T., Petitto, G. S., Lazaryan, A., Singh, A., Xue, E., Dimitrova, D., Hyder, M., McCurdy, S., Im, A., Huber, B., Aljawai, Y. M., Kanakry, J., Milano, F., & Kanakry, C. G. (2025). Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.27662

Vancouver

Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, et al. Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Hematology. 2025. doi:10.1002/ajh.27662

BibTeX
@article{Mehta2025,
  author = {Mehta, Rohtesh S and Choe, Hannah and Saultz, Jennifer and Gong, Zimu and Sharma, Prashant and Al-Juhaishi, Taha and Petitto, Gabriela S and Lazaryan, Aleksandr and Singh, Anurag and Xue, Elisabetta and Dimitrova, Dimana and Hyder, Mustafa and McCurdy, Shannon and Im, Annie and Huber, Bryan and Aljawai, Yosra M and Kanakry, Jennifer and Milano, Filippo and Kanakry, Christopher G},
  title = {Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27662}
}
Kostenlos starten →